Login
$STRO
$9.32 -$0.50 (5.09%) Live

$STRO SEC Filings

Filed On Filing
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –

09 Nov 2026 SCHEDULE 13G
22 Sep 2026 Form 4: Gerber Hans-Peter, CHIEF SCIENTIFIC OFFICER

Received 3,750 shares by exercise or conversion · Gave up 1,345 shares to cover exercise price or tax ($20.6K)

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study –

30 Jul 2026 SCHEDULE 13G
09 Jun 2026 Form 4: Petree Daniel H, Director

Granted 10,000 Stock Option (right to buy)

09 Jun 2026 Form 4: Panek James P, Director

Granted 10,000 Stock Option (right to buy)

09 Jun 2026 Form 4: Dybbs Michael, Director

Granted 10,000 Stock Option (right to buy)

09 Jun 2026 Form 4: Matsui Connie, Director

Granted 10,000 Stock Option (right to buy)

09 Jun 2026 Form 4: Wigginton Jon Marc, Director

Granted 10,000 Stock Option (right to buy)

09 Jun 2026 Form 4: Lobacki Joseph M, Director

Granted 10,000 Stock Option (right to buy)

09 Jun 2026 Form 4: Jagpal Sukhi, Director

Granted 10,000 Stock Option (right to buy)

09 Jun 2026 Form 4: Hunter Heidi, Director

Granted 10,000 Stock Option (right to buy)

08 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 5, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), and the following proposals were adopted:

02 Jun 2026 Form 4: Chow Gregory K., CFO

Received 2,500 shares by exercise or conversion

15 May 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support